Gastrointestinal Drugs Market Trends

Global Gastrointestinal Drugs Market Overview

Gastrointestinal Drugs Market Size was valued at USD 50.9 Billion in 2022. The gastrointestinal drugs market industry is projected to grow from USD 53.5 Billion in 2023 to USD 79.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.03% during the forecast period (2023 - 2032). Growing financing and investment in the life sciences sector and an increase in the prevalence of gastrointestinal disorders are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Par Pharmaceutical, Inc., an operating company of Endo International plc (OTC: ENDPQ) announced in May 2024 that it had started the production of generic ibuprofen-famotidine 800 mg/26.6 mg tablets which are aimed to be copycats for DUEXIS® by Amgen (formerly Horizon Therapeutics). Such pills are used to relieve signs and symptoms of rheumatoid arthritis and osteoarthritis with a reduced risk of ibuprofen-induced stomach or upper intestinal ulcers.

On July 30th, 2023, Viatris Inc. (NASDAQ: VTRS), a global healthcare company and Kindeva Drug Delivery L.P., released Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol as the first generic version of Symbicort® from AstraZeneca under Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). For certain patients with asthma or chronic obstructive pulmonary disease (COPD), Breyna is a drug-device combination product available immediately in two strengths – 80 mcg/4.5 mcg and 160 mcg/4.5 mcg. This includes people aged six years or older with asthma or COPD like chronic bronchitis/emphysema who take these medications to stop their conditions from worsening but they do not provide relief for sudden breathing difficulties.

The Center for Drug Evaluation and Research (CDER) at The U.S. Food and Drug Administration Approved a Bouquet of Medicines in 2023, Which Will Improve the Quality of Life—and Maybe Prolong Lives—of Patients this Year. In fact," CDER approved 55 novel drugs in that year," according to our annual New Drug Therapy Approvals report. A novel drug contains an active ingredient(s) that has never been previously FDA-approved. We also took other important actions, such as expanding the indications or patient populations of some previously approved therapies. Additionally, we allowed new dosage forms or drug formulations and made some prescription drugs available without a prescription.

Gastrointestinal Drugs Market Trends

• An increase in the prevalence of gastrointestinal illnesses is driving the market growth.

Market CAGR for gastrointestinal drugs is being driven. The market expansion is estimated to be throughout the forecasted period to be aided by the rising prevalence of gastrointestinal illnesses. For instance, according to a report from the International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) in July 2022, the prevalence of gastroesophageal reflux disease (GERD) in the world's populations in 2014 ranged from 18 to 28% in North America, 9 to 26% in Europe, 9 to 33% in the Middle East, and 3 to 8% in East Asia, among other places.

Additionally, the  increase in the prevalence of gastrointestinal disorders is a significant driver of the market's expansion for gastrointestinal medications. On the other hand, substantial funding, particularly in scientific research for the development and advancement of these medications, as well as growing awareness about the effectiveness of the treatments and the healing process, are both considerably boosting the market's growth. Additionally, this market is anticipated to grow rapidly in the upcoming years due to technological developments in the treatment procedure. Due to dietary changes, there will likely be a rise in the number of individuals suffering from GI illnesses, boosting the demand for these medications.

Potent pipeline pharmaceuticals like ustekinumab, risankizumab, and ABBV-154 and the rising prescription of biological medications will boost market expansion throughout the anticipated period. In the upcoming years, the market expansion is predicted to be facilitated by the rising number of regulatory approvals for innovative gastrointestinal therapeutic medications. For instance, the U.S. FDA approved RINVOQ (upadacitinib), a prescription drug from AbbVie Inc., in March 2022 to treat severe to moderate ulcerative colitis in adults. The use of RINVOQ to treat individuals who respond poorly to TNF blockers is anticipated to rise.

Likewise, the prescription rate for new & potent medications is anticipated to rise in the upcoming years due to the growing availability of novel treatments for gastrointestinal problems. For instance, BMS gained FDA approval from the United States for Zeposia in May 2021 to treat moderate to severe ulcerative colitis. The only sphingosine 1-phosphate (S1P) receptor modulator approved for the treatment of active UC is a deposit. As a result, it is anticipated that the demand for gastrointestinal drugs will increase throughout the projection period due to the high prevalence of gastrointestinal diseases in the population. Thus, driving the gastrointestinal drugs market revenue.

Gastrointestinal Drugs Market Segment Insights

Gastrointestinal Drugs Drug Class Insights

The  gastrointestinal drugs market segmentation, based on drug class, includes antiemetic & antinauseant, antidiarrheal & laxatives, anti-inflammatory drugs, biologics, acidic neutralizers, and others. The biologics segment dominated the market, accounting for 33% of market revenue (16.79 Billion). Demand for this market segment is being driven by the high prescription rate for biologic and biosimilar medications and the high efficacy of these medications in treating gastrointestinal illnesses like Crohn's disease, ulcerative colitis, GERD, and others.

Gastrointestinal Drugs Application Insights

The  gastrointestinal drugs market segmentation, based on application, includes gastroenteritis, celiac disease, Crohn’s disease, irritable bowel syndrome, inflammatory, ulcerative colitis, and others. The Crohn’s disease category generated the most income (29.5%). The high cost of therapy, rising approval of innovative medications for CD, and rising incidence of Crohn's disease are some major drivers of segment growth.

Gastrointestinal Drugs Route Administration Insights

The  gastrointestinal drugs market segmentation, based on route administration, includes rectal, parenteral, and oral. The oral segment dominated the market, accounting for 38% of market revenue (78.48 Billion). Due to the rising demand for oral medications, their simplicity in use, and their cost-effectiveness. Additionally, the growing acceptance of experimental oral medications like Xeljanz and Rinvoq for treating GI problems is anticipated to fuel sector expansion throughout the projected period.

Gastrointestinal Drugs Distribution Channel Insights

The  gastrointestinal drugs market segmentation, based on distribution channels, includes hospitals, pharmacies, online pharmacies, and retail pharmacies. The retail pharmacies segment dominated the market, accounting for 39% of market revenue (19.85 Billion). The segment is expanding due to increased demand for OTC medications like antacids, anti-emetics, and laxative preparations, as well as unclean dietary habits that frequently cause stomach upsets.

Figure 1  Gastrointestinal Drugs Market, by Distribution Channel, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Gastrointestinal Drugs Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American gastrointestinal drugs market will dominate this market, owing to the presence of numerous market players and their varied strategic efforts.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  Gastrointestinal Drugs Market Share By Region 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's gastrointestinal drugs market accounts for the second-largest market share due to the rising healthcare sector investment and growing knowledge of digestive illnesses and their treatments. Another force in this area is the rising demand for the best and most efficient care. Further, the German gastrointestinal drugs market held the largest market share, and the UK gastrointestinal drugs market was the second-largest growing market in the European region.

The Asia-Pacific gastrointestinal drugs Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to densely populated countries like China and India. An escalating patient population, a growing elderly population, and escalating government investment efforts for healthcare facilities drive the rise in the Asia-Pacific area. Moreover, China’s gastrointestinal drugs market held the largest market share, and the Indian gastrointestinal drugs market was the fastest-growing market in the Asia-Pacific region.

Gastrointestinal Drugs Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the Gastrointestinal Drugs market, grow even more. Additionally, market participants are engaging in a variety of strategic initiatives to increase their  footprint, with important market developments such as the introduction of new products, business contracts, mergers and acquisitions, increased investments, and cooperation with other organisations. To expand and survive in a more competitive and rising market climate, the gastrointestinal drugs industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the  gastrointestinal drugs industry to benefit clients and increase the market sector. In recent years, the gastrointestinal drugs industry has offered some of the most significant advantages to medicine. Major players in the gastrointestinal drugs market, including Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, AbbVie Inc., Valeant Pharmaceuticals Inc., Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., and Sanofi.

Sanofi manufactures pharmaceutical products. The business sells prescription medications, over-the-counter remedies, food supplements, cosmetics, and medical equipment for conditions like diabetes, cancer, gynecology, and cardiology. Sanofi caters to clients all across the world. In May 2020, With the introduction of the new food supplement Buscobiota, Sanofi, a well-known producer of goods like Buscopan for irritable bowel syndrome and Dulcolax for constipation relief, entered the market for digestive health. Buscobiota, which contains two different forms of Bifidobacterium and three different types of Lactobacillus, can be taken as a preventative treatment for chronic constipation.

AbbVie Inc. researches and develops pharmaceutical products. The company produces pharmaceutical medications for specialized treatment fields like immunology, chronic renal disease, hepatitis C, women's health, oncology, and neuroscience. Multiple sclerosis, Parkinson's, and Alzheimer's disease are just a few of the illnesses that AbbVie treats. In March 2022, for treating moderately to highly active ulcerative colitis, the U.S. FDA gave AbbVie Inc. permission to use RINVOQ (upadacitinib), a new medication.

Key Companies in the Gastrointestinal Drugs market include

• Takeda Pharmaceuticals


• Allergan Plc


• Novo Nordisk A/S


• AstraZeneca Plc


• AbbVie Inc.


• Valeant Pharmaceuticals Inc.


• Johnson & Johnson


• Bayer AG


• Boehringer Ingelheim GmbH


• GlaxoSmithKline Plc.


• Janssen Biotech Inc.


• Sanofi

Gastrointestinal Drugs Industry Developments

Sun Pharmaceutical Industries has reportedly signed a licensing agreement with Takeda Pharmaceutical Company in order to commercialize a new gastrointestinal drug throughout India, according to a report published in 2024. The company went into an international non-exclusive patent license pact with Takeda and would sell Vonoprazan tablets of strengths of 10mg and 20mg in India. Vonoprazan is the first oral potassium-competitive acid blocker (PCAB) used for reflux esophagitis and other acid peptic disorders market.

In November 2023, the US FDA approved Vonoprazan as a treatment option for healing and maintenance of all grades of Erosive esophagitis as well as relief from heartburn that accompanies erosive esophagitis, and also as triple therapy including amoxicillin and clarithromycin or dual therapy containing amoxicillin alone for the eradication of Helicobacter pylori (H. pylori) infection in adults.

In its report released last year, Akums Drugs & Pharmaceuticals reported that it has developed a combination drug for gastrointestinal tract disorders. In addition to its earlier statement issued by this contract development & manufacturing organization (CDMO), Rabeprazole + Levosulpiride SR capsules have been launched on receiving approval from DCGI – Drug Controller General of India .

According to a report published in June 2024 Sun Pharma and Cipla on Friday said they have entered into a non-exclusive patent licensing agreement with the Japanese drug maker Takeda Pharmaceutical Company to commercialize Vonoprazan tablets in India.

Janssen Pharmaceutical received European Commission approval for STELARA in September 2019. It is indicated for use in cases of moderate-to-severe active ulcerative colitis among adults only. It is the first biologic treatment that will target IL-12/IL-23 pathway, which is an important therapeutic target in UC. Furthermore, the market is driven by strategic moves by market players such as product launch in untapped markets.

As part of its GI portfolio, Takeda Pharmaceutical Company launched its blockbuster biologic drug Vedolizumab in India in July 2020. The trade name of Vedolizumab in India would be Kynteles. It is used for treatment of chronic inflammatory bowel diseases like ulcerative colitis and Crohn’s disease. In developing countries, there is an increasing incidence of GI disorders.

August 2021 To identify gastrointestinal biomarkers, Arena Pharmaceuticals and Second Genome, a biotechnology firm, have partnered up. Using their sg-4-sight research engine and Arena's Cultivate clinical trial, Second Genome will find microbiome biomarkers to "guide patient stratification and enhance potential treatments."

March 2021 To assess the safety of ustekinumab, Janssen Research and Development, LLC started a phase III clinical investigation. This trial will aid in treating pediatric patients with moderate to severe Crohn's disease.

Gastrointestinal Drugs Market Segmentation

Gastrointestinal Drugs Drug Class Outlook

• Antiemetic And Antinauseants


• Antidiarrheal And Laxatives


• Anti-Inflammatory Drugs


• Biologics


• Acid Neutralizers


• Others

Gastrointestinal Drugs Application Outlook

• Gastroenteritis


• Celiac Disease


• Crohn’s Disease


• Irritable-Bowel-Syndrome


• Inflammatory


• Ulcerative-Colitis


• Others

Gastrointestinal Drugs Route of Administration Outlook

• Rectal


• Parenteral


• Oral

Gastrointestinal Drugs Distribution Channel Outlook

• Hospital Pharmacies


• Online Pharmacies


• Retail Pharmacies

Gastrointestinal Drugs Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America